✉news HealthMedicine first seen 5 h ago, last 1 h ago, peak #16
Eli Lilly CEO Pins Growth Hopes On Retatrutide
Original: Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’
Eli Lilly's chief executive said the company's future has 'never been brighter' as it positions retatrutide, its experimental weight-loss and diabetes drug, as the next major growth driver. The statement follows strong investor interest in Lilly's obesity pipeline, which already includes the blockbuster tirzepatide. Retatrutide is in late-stage trials and is viewed as a potential rival to next-generation obesity treatments. Markets are watching closely as competition in the weight-loss drug market intensifies with Novo Nordisk and others.
Why now: Investors are closely following Eli Lilly's obesity drug pipeline as the weight-loss medicine market booms.
Eli LillyRetatrutideNovo Nordisk
Rank over time, top of the chart is #1. 4 snapshots from 5 h ago to 1 h ago.
Evidence
- Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’ · stocktwits.com
API: https://socialmediatrends-api.osmike.com/v1/trends/94250